Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment could improve outcomes in major stroke

NCT ID NCT05701956

Completed Disease control Sponsor: The First Affiliated Hospital of University of Science and Technology of China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a clot-busting drug (tenecteplase) before mechanical clot removal helps people with a severe type of stroke caused by a blockage in the basilar artery. The trial included 330 adults who were treated between 4.5 and 24 hours after stroke symptoms began. The main goal was to see if the combination led to better recovery (less disability) at 90 days compared to clot removal alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tenecteplase (a clot-busting drug)
What this could lead to
If it works, this could offer a better treatment for severe strokes by combining a clot-busting drug with mechanical clot removal.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Adding tenecteplase may increase bleeding risk without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CEREBROVASCULAR ACCIDENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basilar artery occlusion stroke disorder vertebral artery occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CEREBROVASCULAR ACCIDENT BASILAR ARTERY OCCLUSION STROKE DUE TO BASILAR ARTERY OCCLUSION

Contacts and locations

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.